Literature DB >> 17329284

Comparison of the 40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) with a short-form five-item version (ALSAQ-5) in a longitudinal survey.

C Jenkinson1, R Fitzpatrick, M Swash, G Jones.   

Abstract

OBJECTIVES: To compare results on the 40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) with those gained on the short-form five-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-5) in a longitudinal study.
DESIGN: Postal survey. Copies of the ALSAQ-40 which incorporates the five items of the ALSAQ-5, were completed on two occasions. Respondents were also asked to indicate how much change they had experienced since baseline on each of the five domains of the questionnaire.
SETTING: The database of all patient members of the Motor Neurone Disease Association for England, Wales and Northern Ireland.
SUBJECTS: Nine hundred and twenty-seven patient members returned questionnaires at baseline, and 764 completed questionnaires at both baseline and follow-up.
RESULTS: Results on the five dimensions of the ALSAQ-40 and ALSAQ-5 were found to be highly correlated, and 95% confidence intervals on mean scores were found to overlap for each dimension. The instruments both provide a similar picture of change in terms of their responsiveness. For example, effect sizes were calculated for patients who claimed their health had deteriorated a little since baseline, and gave almost identical results (e.g. for the Physical functioning domain effect sizes of 0.12 and 0.11 were found on the long and short measures respectively).
CONCLUSIONS: Results suggests that the ALSAQ-5 provides similar results to the ALSAQ-40 yet with considerable economy. In instances where a very brief health status measure is required then the ALSAQ-5 may be the instrument of choice.

Entities:  

Mesh:

Year:  2007        PMID: 17329284     DOI: 10.1177/0269215506071123

Source DB:  PubMed          Journal:  Clin Rehabil        ISSN: 0269-2155            Impact factor:   3.477


  6 in total

1.  Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  S Fadilah Abdul Wahid; Zhe Kang Law; Nor Azimah Ismail; Nai Ming Lai
Journal:  Cochrane Database Syst Rev       Date:  2019-12-19

2.  Dignity therapy for people with motor neuron disease and their family caregivers: a feasibility study.

Authors:  Samar M Aoun; Harvey M Chochinov; Linda J Kristjanson
Journal:  J Palliat Med       Date:  2015-01       Impact factor: 2.947

3.  Is dignity therapy feasible to enhance the end of life experience for people with motor neurone disease and their family carers?

Authors:  Brenda Bentley; Samar M Aoun; Moira O'Connor; Lauren J Breen; Harvey Max Chochinov
Journal:  BMC Palliat Care       Date:  2012-09-20       Impact factor: 3.234

Review 4.  Do Psychosocial Interventions Improve Quality of Life and Wellbeing in Adults with Neuromuscular Disorders? A Systematic Review and Narrative Synthesis.

Authors:  Elaine Walklet; Kate Muse; Jane Meyrick; Tim Moss
Journal:  J Neuromuscul Dis       Date:  2016-08-30

5.  A Nation-Wide, Multi-Center Study on the Quality of Life of ALS Patients in Germany.

Authors:  Tara Peseschkian; Isabell Cordts; René Günther; Benjamin Stolte; Daniel Zeller; Carsten Schröter; Ute Weyen; Martin Regensburger; Joachim Wolf; Ilka Schneider; Andreas Hermann; Moritz Metelmann; Zacharias Kohl; Ralf A Linker; Jan Christoph Koch; Boriana Büchner; Ulrike Weiland; Erik Schönfelder; Felix Heinrich; Alma Osmanovic; Thomas Klopstock; Johannes Dorst; Albert C Ludolph; Matthias Boentert; Tim Hagenacker; Marcus Deschauer; Paul Lingor; Susanne Petri; Olivia Schreiber-Katz
Journal:  Brain Sci       Date:  2021-03-14

6.  Feasibility, acceptability, and potential effectiveness of dignity therapy for people with motor neurone disease.

Authors:  Brenda Bentley; Moira O'Connor; Robert Kane; Lauren J Breen
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.